Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia.
Oral treatment of cholesterol-fed rabbits with the PGI2 mimetic cicaprost largely reduces hypercholesterolemia-induced platelet and neutrophil hyperreactivity. In addition, cicaprost prevents atherosclerosis-induced platelet desensitization for PGI2. These effects persist after cicaprost treatment is withdrawn. Since platelets and leukocytes are supposed to contribute to atherogenesis, this suggests a favourable effect of long-term oral PGI2 substitution in hypercholesterolemia.
Hohlfeld
T
T
Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Germany.
Weber
A
A
Schrör
K
K
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000284:Administration, Oral; D000818:Animals; D002784:Cholesterol / Q000097:blood; D003094:Collagen / Q000494:pharmacology; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000097:blood*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D009504:Neutrophils / Q000187:drug effects*; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011817:Rabbits
D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D003094:Collagen; D002784:Cholesterol; D011464:Epoprostenol; C043867:cicaprost